Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705177 | 1.00 | SLC6A4 (1.00) | SLC6A4ADRA1DCYP2D6 | |
| Hydrochloric Acid SCHEMBL5705146 | 0.99 | SLC6A4 (0.98) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL3380974 | 0.99 | SLC6A4 (0.97) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL5705230 | 0.95 | SLC6A4 (0.90) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL9672545 | 0.90 | SLC6A4 (0.81) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL7260934 | 0.89 | ADRA1D (1.00) | SLC6A4ADRA1D | |
| Hydrochloric Acid SCHEMBL7259157 | 0.88 | ADRA1D (0.90) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL14280709 | 0.88 | ADRA1D (0.80) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL14306777 | 0.87 | ADRA1D (0.80) | SLC6A4ADRA1DCYP2D6 | |
| SCHEMBL7259959 | 0.86 | ADRA1D (0.78) | SLC6A4ADRA1DCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | SLC6A4 1968/4885ADRA1D 95/4885CYP2D6 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.